---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031278"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:24:47.463555+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Reviva regains Nasdaq MVLS compliance; still faces bid price delisting risk by Nov 10

## Summary
- Received Nasdaq letter on Oct 14 confirming compliance with $35M minimum market value of listed securities requirement; matter closed.
- Remains non-compliant with $1.00 minimum bid price rule; initial cure period ends November 10, 2025.
- May consider reverse stock split to regain bid price compliance; no assurance of success.
- Previous MVLS non-compliance resolved after 10 consecutive business days above $35M (Sept 30 to Oct 13).

## SEC filing metadata
- accession: 0001437749-25-031278
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/0001437749-25-031278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/rvph20251014_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031278
- JSON: https://secwatch.observer/filing/0001437749-25-031278.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031278.txt

## Source-grounded claims
- claim_id: 26ace889ad54ebcee5f364ebb85e9938e7f892d6
  claim: REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).
  evidence_excerpt: October 14, 2025, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) received a letter (the “MVLS Compliance Letter”) from the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) formally notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities (“MVLS”) requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) and that the MVLS Requirement matter is now closed. The MVLS Compliance Letter was pursuant to a previous notice received on Augu
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/0001437749-25-031278-index.htm
- claim_id: bfce187a3a02f6cd0977c359e13454eef6347029
  claim: REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: May 13, 2025 (the “Minimum Bid Price Notice”), the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days preceding the Minimum Bid Price Notice, the Company is not currently in compliance with Minimum Bid Price Requirement. As previou
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/0001437749-25-031278-index.htm
- claim_id: c86cdd1661867ef39d35d079256084b8b717769d
  claim: REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: May 13, 2025 (the “Minimum Bid Price Notice”), the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days preceding the Minimum Bid Price Notice, the Company is not currently in compliance with Minimum Bid Price Requirement. As previou
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/0001437749-25-031278-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.